BHC Stock Summary and Trading Ideas (Bausch Health Companies | NYSE:BHC)

Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.

Bausch Health Companies trades on the NYSE stock market under the symbol BHC.

As of September 18, 2026, BHC stock price climbed to $5.68 with 267,676 million shares trading.

BHC has a beta of 1.28, meaning it tends to be more sensitive to market movements. BHC has a correlation of 0.07 to the broad based SPY ETF.

BHC has a market cap of $2.12 billion. This is considered a Mid Cap stock.

Last quarter Bausch Health Companies reported $3 billion in Revenue and $1.26 earnings per share. This beat revenue expectation by $196 million and exceeded earnings estimates by $.25.

In the last 3 years, BHC traded as high as $11.46 and as low as $3.96.

The top ETF exchange traded funds that BHC belongs to (by Net Assets): FDLS, DFIS, DFIC, DISV, PPH.

BHC has underperformed the market in the last year with a price return of -16.8% while the SPY ETF gained +16.3%. However, in the short term, BHC had mixed performance relative to the market. It has outperformed in the last 3 months, returning +19.3% vs +3.0% return in SPY. But in the last 2 weeks, BHC shares have been beat by the market, returning -16.0% compared to an SPY return of -1.8%.

BHC support price is $5.46 and resistance is $5.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BHC shares will trade within this expected range on the day.